{"success":true,"data":{"pressRelease":{"id":"41753","rtpr_id":"nGNE8FDzPh","ticker":"IMMX","exchange":"NASDAQ","all_tickers":["IMMX"],"title":"Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock","author":"Globe Newswire","published_at":"2026-05-21T10:30:00.221Z","article_body":"LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc.\n(“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global\nleader in AL Amyloidosis, today announced the pricing of an underwritten\nregistered offering of 16,778,524 shares of its common stock at a price to the\npublic of $8.94 per share. The gross proceeds to Immix from the offering,\nbefore deducting the underwriting discounts, commissions and other offering\nexpenses, are expected to be $150 million. The offering is expected to close\non or about May 22, 2026, subject to the satisfaction of customary closing\nconditions.\n\nImmix intends to use the net proceeds from this offering to fund NXC-201\ndevelopment, working capital and general corporate purposes. Immix believes\nthat the net proceeds from the offering, together with its existing cash and\ncash equivalents, will be sufficient to meet the Company’s operational needs\ninto mid-2028.\n\nMorgan Stanley is acting as the lead book-running manager and BofA Securities\nis acting as book-running manager for the offering. LifeSci Capital, Mizuho\nand Needham & Company are acting as co-lead managers for the offering.\n\nThe securities in the registered offering are being offered and sold pursuant\nto a “shelf” registration statement on Form S-3 (File No. 333-292665),\nincluding a base prospectus, filed with the U.S. Securities and Exchange\nCommission (the “SEC”) on January 9, 2026, and declared effective on\nJanuary 22, 2026. A prospectus supplement and accompanying prospectus\ndescribing the terms of the registered offering will be filed with the SEC and\nwill be available on its website at www.sec.gov. Copies of the prospectus\nsupplement and the accompanying prospectus relating to the offering, when\navailable, may also be obtained from: Morgan Stanley & Co. LLC, attention:\nProspectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014,\nby phone: 1-866-718-1649 or by email: prospectus@morganstanley.com.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy any of the securities described herein, nor shall there be\nany sale of these securities in any state or jurisdiction in which such offer,\nsolicitation or sale would be unlawful prior to registration or qualification\nunder the securities laws of any such state or jurisdiction.\n\nAbout Immix Biopharma, Inc.\n\nImmix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL\nAmyloidosis. AL Amyloidosis is a devastating disease where the immune system,\nthat’s supposed to protect, instead produces toxic light chains, clogging up\nthe heart, kidney and liver, causing organ failure and death. Our lead\ncandidate is sterically-optimized BCMA-targeted chimeric antigen receptor T\n(CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to\nfilter out non-specific activation. NXC-201 teaches the immune system to\nrecognize and eliminate the source of the toxic light chains. NXC-201 is being\nevaluated in the U.S. multi-center study for relapsed/refractory AL\nAmyloidosis NEXICART-2 (NCT06097832), with a potentially registrational\ndesign. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and\nRegenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug\nDesignation (ODD) by FDA and in the EU by the EMA.\n\nForward Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe federal securities laws. Words such as “may,” “might,” “will,”\n“should,” “believe,” “expect,” “anticipate,” “estimate,”\n“continue,” “predict,” “forecast,” “project,” “plan,”\n“intend” or similar expressions, or statements regarding intent, belief,\nor current expectations, are forward-looking statements. These forward-looking\nstatements are based upon current estimates and assumptions and include\nstatements relating to the offering, including the timing of the closing of\nthe offering, the anticipated use of proceeds therefrom, the Company’s cash\nrunway, the potential benefits of the Company’s product candidate CAR-T\nNXC-201 and the timing and results related to clinical trials, including\nplanned trials. While the Company believes these forward-looking statements\nare reasonable, undue reliance should not be placed on any such\nforward-looking statements, which are based on information available to us on\nthe date of this release. These forward-looking statements are subject to\nvarious risks and uncertainties, many of which are difficult to predict that\ncould cause actual results to differ materially from current expectations and\nassumptions from those set forth or implied by any forward-looking statements.\nImportant factors that could cause actual results to differ materially from\ncurrent expectations include, among others, risks and uncertainties relating\nto market conditions; the completion of the proposed offering on the\nanticipated terms or at all; the risk that the estimates for the number of\npatients in the U.S. with relapsed/refractory AL Amyloidosis and the market\nsize are not accurate; the risk that further data from the ongoing U.S. Phase\n1b/2 clinical trial and ex-U.S. Phase 1b/2a clinical trial for CAR-T NXC-201\nwill not be favorably consistent with the data readouts to date; that no drug\nproduct developed by the Company has received FDA pre-market approval or\notherwise been incorporated into a commercial drug product; that success in\nearly phases of pre-clinical and clinicals trials do not ensure later clinical\ntrials will be successful; and those other risks disclosed in the section\n“Risk Factors” included in the Company’s Annual Report on Form 10-K for\nthe fiscal year ended December 31, 2025 and other periodic or current reports\nsubsequently filed with the Securities and Exchange Commission. These reports\nare available at www.sec.gov. Immix Biopharma cautions that the foregoing list\nof important factors is not complete. Immix Biopharma cautions readers not to\nplace undue reliance on any forward-looking statements. Immix Biopharma does\nnot undertake, and specifically disclaims, any obligation to update or revise\nsuch statements to reflect new circumstances or unanticipated events as they\noccur, except as required by law. If we update one or more forward-looking\nstatements, no inference should be drawn that we will make additional updates\nwith respect to those or other forward-looking statements.\n\nContacts\nMike Moyer\nLifeSci Advisors\nmmoyer@lifesciadvisors.com\n\nCompany Contact\nirteam@immixbio.com","article_body_html":"","raw_payload":{"data":{"id":"nGNE8FDzPh","title":"Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock","author":"Globe Newswire","ticker":"IMMX","created":"2026-05-21T10:30:00.221Z","tickers":["IMMX"],"exchange":"NASDAQ","article_body":"LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc.\n(“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global\nleader in AL Amyloidosis, today announced the pricing of an underwritten\nregistered offering of 16,778,524 shares of its common stock at a price to the\npublic of $8.94 per share. The gross proceeds to Immix from the offering,\nbefore deducting the underwriting discounts, commissions and other offering\nexpenses, are expected to be $150 million. The offering is expected to close\non or about May 22, 2026, subject to the satisfaction of customary closing\nconditions.\n\nImmix intends to use the net proceeds from this offering to fund NXC-201\ndevelopment, working capital and general corporate purposes. Immix believes\nthat the net proceeds from the offering, together with its existing cash and\ncash equivalents, will be sufficient to meet the Company’s operational needs\ninto mid-2028.\n\nMorgan Stanley is acting as the lead book-running manager and BofA Securities\nis acting as book-running manager for the offering. LifeSci Capital, Mizuho\nand Needham & Company are acting as co-lead managers for the offering.\n\nThe securities in the registered offering are being offered and sold pursuant\nto a “shelf” registration statement on Form S-3 (File No. 333-292665),\nincluding a base prospectus, filed with the U.S. Securities and Exchange\nCommission (the “SEC”) on January 9, 2026, and declared effective on\nJanuary 22, 2026. A prospectus supplement and accompanying prospectus\ndescribing the terms of the registered offering will be filed with the SEC and\nwill be available on its website at www.sec.gov. Copies of the prospectus\nsupplement and the accompanying prospectus relating to the offering, when\navailable, may also be obtained from: Morgan Stanley & Co. LLC, attention:\nProspectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014,\nby phone: 1-866-718-1649 or by email: prospectus@morganstanley.com.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy any of the securities described herein, nor shall there be\nany sale of these securities in any state or jurisdiction in which such offer,\nsolicitation or sale would be unlawful prior to registration or qualification\nunder the securities laws of any such state or jurisdiction.\n\nAbout Immix Biopharma, Inc.\n\nImmix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL\nAmyloidosis. AL Amyloidosis is a devastating disease where the immune system,\nthat’s supposed to protect, instead produces toxic light chains, clogging up\nthe heart, kidney and liver, causing organ failure and death. Our lead\ncandidate is sterically-optimized BCMA-targeted chimeric antigen receptor T\n(CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to\nfilter out non-specific activation. NXC-201 teaches the immune system to\nrecognize and eliminate the source of the toxic light chains. NXC-201 is being\nevaluated in the U.S. multi-center study for relapsed/refractory AL\nAmyloidosis NEXICART-2 (NCT06097832), with a potentially registrational\ndesign. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and\nRegenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug\nDesignation (ODD) by FDA and in the EU by the EMA.\n\nForward Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe federal securities laws. Words such as “may,” “might,” “will,”\n“should,” “believe,” “expect,” “anticipate,” “estimate,”\n“continue,” “predict,” “forecast,” “project,” “plan,”\n“intend” or similar expressions, or statements regarding intent, belief,\nor current expectations, are forward-looking statements. These forward-looking\nstatements are based upon current estimates and assumptions and include\nstatements relating to the offering, including the timing of the closing of\nthe offering, the anticipated use of proceeds therefrom, the Company’s cash\nrunway, the potential benefits of the Company’s product candidate CAR-T\nNXC-201 and the timing and results related to clinical trials, including\nplanned trials. While the Company believes these forward-looking statements\nare reasonable, undue reliance should not be placed on any such\nforward-looking statements, which are based on information available to us on\nthe date of this release. These forward-looking statements are subject to\nvarious risks and uncertainties, many of which are difficult to predict that\ncould cause actual results to differ materially from current expectations and\nassumptions from those set forth or implied by any forward-looking statements.\nImportant factors that could cause actual results to differ materially from\ncurrent expectations include, among others, risks and uncertainties relating\nto market conditions; the completion of the proposed offering on the\nanticipated terms or at all; the risk that the estimates for the number of\npatients in the U.S. with relapsed/refractory AL Amyloidosis and the market\nsize are not accurate; the risk that further data from the ongoing U.S. Phase\n1b/2 clinical trial and ex-U.S. Phase 1b/2a clinical trial for CAR-T NXC-201\nwill not be favorably consistent with the data readouts to date; that no drug\nproduct developed by the Company has received FDA pre-market approval or\notherwise been incorporated into a commercial drug product; that success in\nearly phases of pre-clinical and clinicals trials do not ensure later clinical\ntrials will be successful; and those other risks disclosed in the section\n“Risk Factors” included in the Company’s Annual Report on Form 10-K for\nthe fiscal year ended December 31, 2025 and other periodic or current reports\nsubsequently filed with the Securities and Exchange Commission. These reports\nare available at www.sec.gov. Immix Biopharma cautions that the foregoing list\nof important factors is not complete. Immix Biopharma cautions readers not to\nplace undue reliance on any forward-looking statements. Immix Biopharma does\nnot undertake, and specifically disclaims, any obligation to update or revise\nsuch statements to reflect new circumstances or unanticipated events as they\noccur, except as required by law. If we update one or more forward-looking\nstatements, no inference should be drawn that we will make additional updates\nwith respect to those or other forward-looking statements.\n\nContacts\nMike Moyer\nLifeSci Advisors\nmmoyer@lifesciadvisors.com\n\nCompany Contact\nirteam@immixbio.com"},"type":"article","timestamp":"2026-05-21T10:30:00.29853399Z","server_sent_at_ms":1779359400298},"received_at":"2026-05-21T10:30:00.471Z","source_url":null},"analysis":{"id":"31192","press_release_id":"41753","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"offering","narrative":"Immix Biopharma priced a $150 million underwritten offering of 16.8 million shares at $8.94 per share.\n\nThe company intends to use the net proceeds to fund the development of its lead CAR-T candidate NXC-201, working capital, and general corporate purposes.\n\nManagement stated that the proceeds, combined with existing cash, will fund operations into mid-2028. Morgan Stanley and BofA Securities led the offering.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Immix raises $150M via dilutive offering to fund NXC-201 development through mid-2028."},"keyFigures":{"dealValueUsd":150000000,"offeringPrice":8.94,"sharesOffered":16778524,"customDimensions":{"cash_runway_extension":"mid-2028"}},"quotedText":"Immix believes that the net proceeds from the offering, together with its existing cash and cash equivalents, will be sufficient to meet the Company’s operational needs into mid-2028.","namedEntities":{"people":[{"name":"Mike Moyer","role":"LifeSci Advisors"}],"products":["NXC-201"],"companies":[{"name":"Immix Biopharma, Inc.","ticker":"IMMX","relationship":"filer"},{"name":"Morgan Stanley","relationship":"lead book-running manager"},{"name":"BofA Securities","relationship":"book-running manager"},{"name":"LifeSci Capital","relationship":"co-lead manager"},{"name":"Mizuho","relationship":"co-lead manager"},{"name":"Needham & Company","relationship":"co-lead manager"}],"dollarAmounts":[{"amount":"$150 million","context":"gross proceeds of the offering"},{"amount":"$8.94","context":"price per share to the public"}]},"materialImpact":{"score":4,"reasoning":"A $150M public offering represents significant dilution for a mid-cap biotech. While the proceeds extend cash runway to mid-2028, the immediate impact is share count expansion and potential downward price pressure. The use of proceeds for development is standard, but the size of the raise relative to typical biotech market caps warrants a high impact score."},"tickerRelevance":{"others":[],"primary":"IMMX"},"globalImportance":35,"audienceRelevance":25,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"dilutive_offering","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"neutral","retailFavoriteBoost":0}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bearish","material_impact_score":4,"narrative":"Immix Biopharma priced a $150 million underwritten offering of 16.8 million shares at $8.94 per share.\n\nThe company intends to use the net proceeds to fund the development of its lead CAR-T candidate NXC-201, working capital, and general corporate purposes.\n\nManagement stated that the proceeds, combined with existing cash, will fund operations into mid-2028. Morgan Stanley and BofA Securities led the offering.","key_figures":{"dealValueUsd":150000000,"offeringPrice":8.94,"sharesOffered":16778524,"customDimensions":{"cash_runway_extension":"mid-2028"}},"named_entities":{"people":[{"name":"Mike Moyer","role":"LifeSci Advisors"}],"products":["NXC-201"],"companies":[{"name":"Immix Biopharma, Inc.","ticker":"IMMX","relationship":"filer"},{"name":"Morgan Stanley","relationship":"lead book-running manager"},{"name":"BofA Securities","relationship":"book-running manager"},{"name":"LifeSci Capital","relationship":"co-lead manager"},{"name":"Mizuho","relationship":"co-lead manager"},{"name":"Needham & Company","relationship":"co-lead manager"}],"dollarAmounts":[{"amount":"$150 million","context":"gross proceeds of the offering"},{"amount":"$8.94","context":"price per share to the public"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-21T10:31:13.698Z","global_importance":35,"audience_relevance":25,"importance_components":{"tickerTier":"mid-cap","eventGravity":"dilutive_offering","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"neutral","retailFavoriteBoost":0}},"durationMs":42506,"modelName":"george-droid-qwen-72b"}}